주의력 결핍 과잉행동장애(ADHD) 역학 분석 및 예측(2026년)

The Global Attention Deficit Hyperactivity Disorder (ADHD) polupation is projected to grow at a CAGR of 1.4% over the forecast period, increasing from 38.59 million patients in 2026 to 43.86 million patients by 2035.

The global attention deficit hyperactivity disorder (ADHD) epidemiology analysis market is gaining strategic importance as healthcare providers, pharmaceutical companies, research organizations, and policymakers seek comprehensive insights into the prevalence, incidence, demographic distribution, disease burden, diagnosis rates, and treatment patterns associated with ADHD. Epidemiological analysis provides the foundation for clinical development, commercial forecasting, healthcare planning, and resource allocation by identifying current and future patient populations across pediatric, adolescent, and adult age groups. As awareness of ADHD continues to increase worldwide, epidemiological intelligence is becoming an essential component of market strategy and public health planning.

ADHD is one of the most common neurodevelopmental disorders, affecting individuals throughout childhood and often persisting into adulthood. Historically regarded primarily as a childhood condition, growing clinical evidence has demonstrated that ADHD frequently continues across the lifespan, resulting in increasing diagnosis among adults. Improvements in diagnostic criteria, greater awareness among healthcare professionals, expanded mental health screening, and stronger public education initiatives have contributed to a growing diagnosed patient population across multiple geographic regions.

Epidemiological analysis has become increasingly sophisticated through the integration of electronic health records, national healthcare databases, insurance claims, patient registries, artificial intelligence, and real-world evidence platforms. These resources enable detailed assessment of disease prevalence, incidence, gender distribution, age-specific trends, treatment patterns, healthcare utilization, and long-term clinical outcomes. Such information supports pharmaceutical pipeline development, clinical trial recruitment, healthcare policy formulation, and commercial market forecasting.

The burden of ADHD extends beyond clinical symptoms to include educational challenges, reduced workplace productivity, psychiatric comorbidities, healthcare costs, and diminished quality of life. As governments expand investment in mental health services and healthcare systems improve access to neurodevelopmental disorder diagnosis, demand for comprehensive epidemiological analysis continues to increase. Growing recognition of adult ADHD, advances in precision medicine, and increasing adoption of digital healthcare technologies are expected to further strengthen the role of epidemiological intelligence throughout the forecast period.

Market Drivers

Rising Global ADHD Prevalence

• Increasing awareness and improved diagnostic capabilities continue to expand the identified ADHD patient population across children, adolescents, and adults.
• Earlier diagnosis, better healthcare access, and broader recognition of adult ADHD are supporting more accurate epidemiological assessments worldwide.

Improved Diagnostic Awareness

• Healthcare providers are increasingly recognizing ADHD across diverse patient populations, including adults who were previously undiagnosed during childhood.
• Educational campaigns, physician training, and standardized diagnostic guidelines are improving disease detection and expanding the diagnosed population.

Expansion of Real-World Healthcare Data

• Electronic medical records, insurance databases, patient registries, and digital health platforms are improving the quality of epidemiological research.
• Large-scale healthcare datasets enable continuous monitoring of disease prevalence, treatment utilization, and long-term patient outcomes.

Growing Investment in Mental Health Research

• Governments, academic institutions, pharmaceutical companies, and public health organizations continue to increase investment in ADHD research and epidemiological surveillance.
• These initiatives improve disease monitoring while supporting healthcare planning and therapeutic development.

Increasing Focus on Adult ADHD

• Recognition that ADHD frequently persists throughout adulthood has significantly expanded epidemiological research.
• Adult prevalence studies are improving understanding of disease burden while creating new opportunities for therapeutic development and healthcare planning.

Market Restraints

Underdiagnosis in Many Regions

• A considerable proportion of individuals with ADHD remain undiagnosed due to limited awareness, inadequate access to specialists, and variations in healthcare infrastructure.
• Underdiagnosis continues to affect the accuracy of epidemiological estimates, particularly in low-income and middle-income countries.

Variability in Diagnostic Criteria

• Differences in diagnostic guidelines, screening methods, reporting systems, and healthcare practices across countries create challenges when comparing epidemiological data internationally.
• These variations may influence prevalence estimates and long-term forecasting.

Limited Mental Health Infrastructure

• Many developing healthcare systems continue to experience shortages of psychiatrists, psychologists, and specialized diagnostic services.
• Limited healthcare capacity may delay diagnosis and reduce the completeness of epidemiological reporting.

Technology and Segment Insights

By Disease Type

• Combined-type ADHD represents a substantial proportion of diagnosed cases due to the presence of both inattentive and hyperactive symptoms.
• Predominantly inattentive ADHD accounts for a growing share of diagnosed patients, particularly among adolescents and adults where symptoms often remain unrecognized for extended periods.
• Predominantly hyperactive-impulsive ADHD represents an important segment, especially among younger pediatric populations.

By Age Group

• Children remain the largest diagnosed patient population due to routine developmental screening and school-based identification programs.
• Adolescents continue to represent an important epidemiological segment as diagnosis improves during secondary education.
• Adult ADHD represents one of the fastest-growing epidemiological categories owing to increasing awareness, improved diagnostic pathways, and greater recognition of persistent symptoms throughout adulthood.

By Gender

• Male patients continue to account for the majority of diagnosed ADHD cases, particularly during childhood.
• However, increasing recognition of underdiagnosis among females is contributing to improved identification across adolescent and adult populations. Enhanced understanding of gender-specific symptom presentation is improving diagnostic accuracy.

By End User

• Pharmaceutical companies represent the largest users of ADHD epidemiological analysis for commercial forecasting, patient segmentation, and clinical development planning.
• Healthcare providers utilize epidemiological studies to optimize screening programs, treatment planning, and healthcare resource allocation.
• Academic institutions, government agencies, contract research organizations, and healthcare consulting firms also rely extensively on epidemiological intelligence to support scientific research, public health policy, and market assessment.

Regional Insights

• North America dominates the global ADHD epidemiology analysis market due to advanced healthcare infrastructure, comprehensive electronic health record systems, extensive epidemiological research, and high diagnosis rates. The United States continues to lead in ADHD surveillance, clinical research, and healthcare analytics, supported by increasing recognition of adult ADHD.
• Europe represents a significant market supported by established healthcare systems, expanding mental health awareness, national disease registries, and collaborative epidemiological research. Countries including Germany, the United Kingdom, France, Italy, and Spain continue to strengthen ADHD surveillance and diagnostic capabilities.
• Asia Pacific is expected to experience the fastest growth during the forecast period. Rising healthcare expenditure, expanding psychiatric services, increasing public awareness, and improving access to diagnosis are strengthening epidemiological research across China, Japan, India, South Korea, and Australia.
• Latin America and the Middle East & Africa are gradually improving ADHD diagnosis through healthcare modernization, expanded specialist services, and increased government investment in mental health programs.

Competitive and Strategic Outlook

• The global ADHD epidemiology analysis market is supported by epidemiology research organizations, healthcare analytics companies, pharmaceutical consulting firms, contract research organizations, and real-world evidence providers. Competition increasingly focuses on delivering accurate patient population estimates, disease forecasting models, treatment utilization analysis, and demographic segmentation to support pharmaceutical development and healthcare decision-making.
• Organizations are investing in artificial intelligence, predictive analytics, electronic health records integration, and real-world evidence platforms to improve epidemiological accuracy and forecasting capabilities. Strategic collaborations between pharmaceutical companies, healthcare providers, academic institutions, and government agencies continue to strengthen data quality and analytical depth.
• Future market development is expected to emphasize precision epidemiology, longitudinal disease monitoring, digital health integration, and advanced predictive models capable of supporting personalized medicine, healthcare policy, and commercial planning across the global ADHD treatment landscape.

Conclusion

The global ADHD epidemiology analysis market is expected to expand steadily as awareness, diagnosis, and understanding of ADHD continue to improve across both pediatric and adult populations. Rising disease recognition, expanding healthcare databases, increasing investment in mental health research, and broader adoption of advanced healthcare analytics are expected to drive sustained demand for epidemiological intelligence. Although challenges related to underdiagnosis, regional variability, and healthcare accessibility remain, ongoing advances in digital health, real-world evidence, and precision epidemiology will continue to improve understanding of ADHD disease burden and support strategic decision-making across healthcare and pharmaceutical industries.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Overview
• 1.2 Key Epidemiology Highlights
• 1.3 Global ADHD Disease Burden Snapshot
• 1.4 Major Epidemiology Trends and Forecast Insights
• 1.5 Key Growth Drivers and Challenges
• 1.6 Emerging Trends in ADHD Diagnosis and Management
• 1.7 Analyst Perspective and Strategic Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Attention Deficit Hyperactivity Disorder (ADHD)
  • 2.1.1 Definition and Clinical Overview
  • 2.1.2 Disease Classification
  • 2.1.3 Etiology and Risk Factors
  • 2.1.4 Neurobiology and Pathophysiology
  • 2.1.5 Genetic and Environmental Influences
• 2.2 ADHD Disease Classification by Presentation
  • 2.2.1 Predominantly Inattentive Presentation
  • 2.2.2 Predominantly Hyperactive-Impulsive Presentation
  • 2.2.3 Combined Presentation
• 2.3 Diagnostic Criteria and Assessment Tools
  • 2.3.1 DSM-5 Diagnostic Criteria
  • 2.3.2 ICD-Based Classification
  • 2.3.3 Clinical Assessment Scales
  • 2.3.4 Differential Diagnosis
  • 2.3.5 Screening and Early Diagnosis Trends
• 2.4 Global ADHD Epidemiology Overview
  • 2.4.1 Incidence Analysis (2021-2035)
  • 2.4.2 Prevalence Analysis (2021-2035)
  • 2.4.3 Diagnosed Prevalence
  • 2.4.4 Treated Prevalence
  • 2.4.5 Gender-wise Epidemiology
  • 2.4.6 Age-wise Epidemiology
  • 2.4.7 Pediatric Population Analysis
  • 2.4.8 Adolescent Population Analysis
  • 2.4.9 Adult ADHD Population Analysis
• 2.5 Epidemiology by Disease Severity
  • 2.5.1 Mild ADHD
  • 2.5.2 Moderate ADHD
  • 2.5.3 Severe ADHD
• 2.6 Comorbidity Burden Analysis
  • 2.6.1 Anxiety Disorders
  • 2.6.2 Depression
  • 2.6.3 Autism Spectrum Disorder
  • 2.6.4 Oppositional Defiant Disorder
  • 2.6.5 Learning Disabilities
  • 2.6.6 Substance Use Disorders

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Increasing ADHD Diagnosis Rates
  • 3.2.2 Rising Awareness and Screening Programs
  • 3.2.3 Expanding Adult ADHD Recognition
  • 3.2.4 Availability of Long-Acting Therapeutics
• 3.3 Market Restraints
  • 3.3.1 Drug Shortages and Supply Constraints
  • 3.3.2 Concerns Regarding Abuse Potential
  • 3.3.3 Underdiagnosis in Emerging Economies
  • 3.3.4 Social Stigma and Misconceptions
• 3.4 Market Opportunities
  • 3.4.1 Growth in Adult ADHD Therapeutics
  • 3.4.2 Digital Therapeutics and Remote Monitoring
  • 3.4.3 Novel Non-Stimulant Therapies
  • 3.4.4 Precision Medicine Approaches
• 3.5 Porter's Five Forces Analysis
  • 3.5.1 Threat of New Entrants
  • 3.5.2 Bargaining Power of Suppliers
  • 3.5.3 Bargaining Power of Buyers
  • 3.5.4 Threat of Substitutes
  • 3.5.5 Competitive Rivalry
• 3.6 PESTLE Analysis
• 3.7 Value Chain Analysis
• 3.8 Unmet Needs Analysis

4. Commercial & Market Access

• 4.1 Commercial Landscape Overview
• 4.2 Pricing Analysis
• 4.3 Reimbursement Scenario
• 4.4 Patient Access Programs
• 4.5 Generic Competition Analysis
• 4.6 Branded vs Generic Market Assessment
• 4.7 Healthcare Expenditure Impact on ADHD Treatment

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends in ADHD Treatment
• 5.2 Emerging Therapeutic Modalities
  • 5.2.1 Novel Stimulants
  • 5.2.2 Non-Stimulant Therapies
  • 5.2.3 Digital Therapeutics
  • 5.2.4 Combination Therapies
• 5.3 Pipeline Landscape Overview
• 5.4 Pipeline Analysis by Clinical Phase
  • 5.4.1 Phase I Assets
  • 5.4.2 Phase II Assets
  • 5.4.3 Phase III Assets
• 5.5 Pipeline Analysis by Mechanism of Action
  • 5.5.1 Norepinephrine Reuptake Inhibitors
  • 5.5.2 Dopamine and Norepinephrine Modulators
  • 5.5.3 Triple Monoamine Reuptake Inhibitors
  • 5.5.4 Orexin Receptor Modulators
  • 5.5.5 Other Novel Mechanisms
• 5.6 Pipeline Analysis by Modality
  • 5.6.1 Small Molecules
  • 5.6.2 Digital Therapeutics
  • 5.6.3 Combination Products
• 5.7 Clinical Trial Landscape
  • 5.7.1 Active Trials by Phase
  • 5.7.2 Trial Distribution by Geography
  • 5.7.3 Trial Distribution by Patient Population
  • 5.7.4 Key Trial Endpoints

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Treatment Guidelines Overview
• 6.3 Pharmacological Treatment Landscape
  • 6.3.1 Stimulant Therapies
    • 6.3.1.1 Methylphenidate-Based Products
    • 6.3.1.2 Amphetamine-Based Products
  • 6.3.2 Non-Stimulant Therapies
    • 6.3.2.1 Atomoxetine
    • 6.3.2.2 Guanfacine Extended Release
    • 6.3.2.3 Clonidine Extended Release
    • 6.3.2.4 Viloxazine Extended Release
• 6.4 Approved ADHD Drugs by Drug Class
• 6.5 Treatment Algorithm by Age Group
  • 6.5.1 Children
  • 6.5.2 Adolescents
  • 6.5.3 Adults
• 6.6 Non-Pharmacological Interventions
  • 6.6.1 Behavioral Therapy
  • 6.6.2 Cognitive Behavioral Therapy
  • 6.6.3 Parent Training Programs
  • 6.6.4 Educational Interventions
• 6.7 Digital Therapeutics and Neurostimulation Approaches

7. Global Attention Deficit Hyperactivity Disorder (ADHD) Epidemiology Report Size & Forecast

• 7.1 Global Market Overview
• 7.2 Historical Market Size Analysis (2021-2025)
• 7.3 Market Forecast Analysis (2026-2035)
• 7.4 Market Attractiveness Analysis
• 7.5 Absolute Dollar Opportunity Analysis
• 7.6 Incremental Growth Opportunity Analysis

8. Global Attention Deficit Hyperactivity Disorder (ADHD) Epidemiology Report Segmentation

• 8.1 By Drug Class
  • 8.1.1 Stimulants
    • 8.1.1.1 Methylphenidate-Based Drugs
    • 8.1.1.2 Amphetamine-Based Drugs
  • 8.1.2 Non-Stimulants
    • 8.1.2.1 Atomoxetine
    • 8.1.2.2 Alpha-2 Adrenergic Agonists
    • 8.1.2.3 Others
• 8.2 By Indication
  • 8.2.1 Pediatric ADHD
  • 8.2.2 Adolescent ADHD
  • 8.2.3 Adult ADHD
• 8.3 By Route of Administration
  • 8.3.1 Oral
  • 8.3.2 Transdermal
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Specialty Clinics
  • 8.4.3 Psychiatric Centers
  • 8.4.4 Homecare Settings
• 8.5 By Distribution Channel
  • 8.5.1 Hospital Pharmacies
  • 8.5.2 Retail Pharmacies
  • 8.5.3 Online Pharmacies

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Forecast
  • 9.1.2 Epidemiology Overview
  • 9.1.3 Demand Drivers
  • 9.1.4 Regional Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Forecast
  • 9.2.2 Epidemiology Overview
  • 9.2.3 Demand Drivers
  • 9.2.4 Regional Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Forecast
  • 9.3.2 Epidemiology Overview
  • 9.3.3 Demand Drivers
  • 9.3.4 Regional Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Forecast
  • 9.4.2 Epidemiology Overview
  • 9.4.3 Demand Drivers
  • 9.4.4 Regional Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Forecast
  • 9.5.2 Epidemiology Overview
  • 9.5.3 Demand Drivers
  • 9.5.4 Regional Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement
  • 10.1.5 Key Companies and Products Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
• 11.3 European Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Controlled Substance Regulations for ADHD Medications
• 11.8 Prescription and Monitoring Requirements
• 11.9 Intellectual Property and Patent Landscape
• 11.10 Regulatory Trends and Future Outlook

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Approved Product Comparison
• 12.5 Pipeline Competitiveness Assessment
• 12.6 Strategic Developments
  • 12.6.1 Product Launches
  • 12.6.2 Regulatory Approvals
  • 12.6.3 Collaborations and Partnerships
  • 12.6.4 Acquisitions and Licensing Agreements

13. Company Profiles

• 13.1 Takeda Pharmaceutical Company Limited
• 13.2 Supernus Pharmaceuticals, Inc.
• 13.3 Johnson & Johnson
• 13.4 Novartis AG
• 13.5 Neos Therapeutics
• 13.6 Eli Lilly and Company
• 13.7 Amedra
• 13.8 Teva Pharmaceuticals
• 13.9 Arbor Pharmaceuticals, LLC
• 13.10 Tris Pharma, Inc.

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Forecast of Diagnosed and Treated Population
• 14.3 Emerging Treatment Paradigms
• 14.4 Next-Generation Therapeutic Opportunities
• 14.5 Digital Health Integration in ADHD Management
• 14.6 Strategic Recommendations for Stakeholders
• 14.7 Long-Term Market Outlook (2026-2035)

15. Methodology

• 15.1 Research Objectives
• 15.2 Study Scope and Assumptions
• 15.3 Data Collection Methodology
• 15.4 Secondary Research Sources
• 15.5 Primary Research
• 15.6 Epidemiology Forecasting Methodology
• 15.7 Market Estimation and Forecasting Models
• 15.8 Data Validation and Triangulation
• 15.9 Limitations